|
KMID : 0939920070390020749
|
|
대한암학회지
2007 Volume.39 No. 2 p.749 ~ p.53
|
|
|
Phase II Study of Docetaxel and Cisplatin as First-line Chemotherapy in Patients with Recurrent or Metastatic Gastric Cancer.
|
|
Kim Kyoung-Ha
Jeung Ki-Ju
Kim Hyun-Jung
Bae Sang-Byung
Kim Chan-Kyu
Lee Nam-Su
Lee Kyu-Taek
Park Sung-Kyu
Won Jong-Ho
Hong Dae-Sik
Park Hee-Sook
|
|
|
Abstract
|
|
|
Purpose: Palliative chemotherapy for patients with recurrent or metastatic gastric cancer has been shown to have a survival benefit. Docetaxel monotherapy has achieved appreciable results for treating gastric cancer. We investigated the clinical efficacy and feasibility of a docetaxel and cisplatin combination regimen for patients suffering with recurrent or metastatic gastric cancer.
Materials and Methods:Patients with histologically proven, bidimensionally measurable lesions of recurrent or metastatic gastric cancer, and they had an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 and no prior palliative chemotherapy were eligible for this study. The combination chemotherapy regimen consisted of docetaxel 75 mg/m2 plus cisplatin 75 mg/m2 on day 1, and this was repeated every 3 weeks until disease progression.
Results: 32 patients were enrolled from 2002 to 2005. The objective response rate was 31.3% (95% confidenceinterval (CI): 14.2~48.2%) with no CR. The disease control rate was 59.4%. At a median follow up of 38.9 months, the median overall survival was 7.4 months (95% CI: 6.3~8.5). The median time to progression was 4.7 months (95% CI: 3.1~6.3). During a total of 106 cycles, grade 3 or 4 hematological toxicities were observed as follows: neutropenia (39 of 106 cycles) and anemia (3 of 106 cycles). The grade 3 or 4 non-hematological toxicities included anorexia (18.9%) and nausea/vomiting (21.7%).
Conclusions: Docetaxel and cisplatin combination chemotherapy showed promising anti-tumor activity and this was well tolerated as a first-line treatment for patients with recurrent or metastatic gastric cancer. Further large, randomized phase III studies are warranted.
|
|
|
KEYWORD
|
|
|
Docetaxel, Cisplatin, Stomach neoplasms
|
|
|
FullTexts / Linksout information
|
|
 
|
|
|
Listed journal information
|
|
    
|